Tavapadon

Posted results on ClinicalTrials.gov for NCT04542499

• Change From Baseline in the Total "On" Time Without Troublesome Dyskinesia Based on the 2-day Average of the Self-completed Home Diary for Motor Function Status (Hauser Diary) (hours)
  • Placebo vs Tavapadon: LS Mean of Difference 1.103 (95% CI 0.553 to 1.653), p-value <0.0001, Mixed-effect Model Repeated Measurement, superiority

Serious adverse events (All-cause mortality were reported from enrollment to the end of study, median time on follow up (median time subjects were followed) was 190 and 189 days for Placebo and Tavapadon, respectively. Treatment-emergent adverse events and serious adverse events were collected from first dose of study drug until 4 weeks after the last dose of study drug; mean duration on study drug was 169.6 and 151.7 days for Placebo and Tavapadon, respectively.): Placebo 14 of 255; Tavapadon 17 of 252

Source: ClinicalTrials.gov results for NCT04542499 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for TEMPO-2

• Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score (score on a scale)
  • Placebo vs Tavapadon: LS Mean of Difference -9.1 (95% CI -11.7 to -6.5), p-value <0.0001, Mixed-effect Model Repeated Measurement, superiority

Serious adverse events (All-cause mortality were reported from enrollment until 4 weeks after the end of study. Treatment-emergent adverse events and serious adverse events were collected from first dose of study drug until 4 weeks after the last dose of study drug. Mean duration on study drug was 176.7 and 144.5 days for Placebo and Tavapadon, respectively. Median time on follow up (median time subjects were followed) was 200 and 198 days for Placebo and Tavapadon, respectively.): Placebo 2 of 153; Tavapadon 7 of 151

Source: ClinicalTrials.gov results for NCT04223193 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.

Posted results on ClinicalTrials.gov for TEMPO-1

• Change From Baseline in the MDS-UPDRS Parts II and III Combined Score (score on a scale)
  • Placebo vs Tavapadon 5 mg: LS Mean of Difference -11.5 (95% CI -13.8 to -9.2), p-value <0.0001, Mixed-effect Model Repeated Measurement, superiority
  • Placebo vs Tavapadon 15 mg: LS Mean of Difference -12.1 (95% CI -14.4 to -9.8), p-value <0.0001, Mixed-effect Model Repeated Measurement, superiority

Serious adverse events (All-cause mortality was reported from enrollment until 4 weeks after the last dose of study drug. Treatment-emergent adverse events and serious adverse events were collected from the first dose of study drug until 4 weeks after the dose of study drug for all Arms. Mean duration on study drug was 27 weeks. Median time on study was 190, 190, 189 days for Placebo, Tavapadon 5 mg, and Tavapadon 15 mg, respectively.): Placebo 11 of 175; Tavapadon 5mg QD 4 of 177; Tavapadon 15mg QD 10 of 177

Source: ClinicalTrials.gov results for NCT04201093 (opens in a new tab)· imported 26 Oct 2026

Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.